Upadacitinib is an oral, second-generation JAK1 inhibitor currently approved by the FDA and EMA for the treatment of rheumatoid arthritis, axial spondylarthritis, Crohn’s disease (CD), ulcerative colitis, and atopic dermatitis in adult patients. This evidence concerns the gene JAK1 and Crohn disease.